abrdn plc Makes New Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

abrdn plc bought a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 99,340 shares of the company’s stock, valued at approximately $1,313,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. China Universal Asset Management Co. Ltd. increased its holdings in Syndax Pharmaceuticals by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company’s stock worth $239,000 after buying an additional 1,732 shares during the last quarter. R Squared Ltd bought a new position in shares of Syndax Pharmaceuticals during the 4th quarter valued at approximately $26,000. KBC Group NV increased its stake in shares of Syndax Pharmaceuticals by 104.8% during the 4th quarter. KBC Group NV now owns 6,954 shares of the company’s stock worth $92,000 after purchasing an additional 3,559 shares during the last quarter. Inspire Investing LLC raised its holdings in shares of Syndax Pharmaceuticals by 44.5% in the 4th quarter. Inspire Investing LLC now owns 30,792 shares of the company’s stock worth $407,000 after purchasing an additional 9,484 shares during the period. Finally, Assenagon Asset Management S.A. lifted its stake in Syndax Pharmaceuticals by 343.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company’s stock valued at $27,292,000 after purchasing an additional 1,598,428 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Stifel Nicolaus raised their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. UBS Group assumed coverage on Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a “buy” rating and a $37.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, December 10th. JPMorgan Chase & Co. lifted their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday, November 21st. Finally, Citigroup boosted their price target on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $36.20.

Syndax Pharmaceuticals Trading Down 2.5 %

Syndax Pharmaceuticals stock opened at $15.13 on Tuesday. The firm’s 50 day simple moving average is $14.06 and its 200 day simple moving average is $17.40. Syndax Pharmaceuticals, Inc. has a 1-year low of $12.06 and a 1-year high of $25.34. The firm has a market capitalization of $1.29 billion, a PE ratio of -4.17 and a beta of 0.90.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).